Hepatitis B in special situations;Hepatitis B en situaciones especiales

Gastroenterologia y Hepatologia

Volumn 29, Issue SUPPL. 2, 2006, Pages 76-81

  Torres Salinas, M ^a,b  

^a HOSPITAL DE L ESPERIT SANT   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HYPERIMMUNE GLOBULIN; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE;

CONFERENCE PAPER; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; SANITATION; VACCINATION;

EID: 34547923247     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13097583     Document Type: Conference Paper

References (10)

1. CDC. Update US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR. 2001;50RR-11:1-42.
2. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. 2005;54RR-16:1-32.
3. CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. 2001;50 RR-5:1-43.
4. Tong NK, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodilysis and hemodialysis patients. Kidney Int. 2005;68:2298-303.
5. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation. 2005;801086-92.
6. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004;24:547-51.
7. Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426-32.
8. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209-20.
9. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597-603.
10. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857-61.